Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne

/PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces initiation of the Phase III clinical trial of fatty acid synthase (FASN)...

Related Keywords

China ,Hangzhou ,Zhejiang ,Hong Kong ,Huashan ,Henan ,Shaoxing ,Chinese ,Ann Pharmacother ,Leihong Xiang ,Jinzij Wu ,Sagimet Biosciences Inc ,National Medical Products Administration ,Institute Of Dermatology ,Fudan University ,Ascletis Pharma Inc ,Physician Of Dermatological Department ,Dermatology Division Of Chinese Medical Doctor Association ,Hong Kong Stock Exchange ,Prnewswire Ascletis Pharma Inc ,Drug Evaluation ,Institutional Review Board ,Huashan Hospital ,Professor Leihong Xiang ,Global Assessment ,Greater China ,Sagimet Biosciences ,Chief Physician ,Dermatological Department ,Executive Deputy Director ,Deputy Director ,Dermatology Division ,Chinese Medical Doctor Association ,Novel Androgen Receptor Inhibitor Fits Into ,Acne Treatment ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,